Biopharma Stock Alert for VIVUS Inc. Issued by Beacon Equity


DALLAS, Feb. 16, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biopharmaceutical company VIVUS Inc. (Nasdaq:VVUS). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: http://www.beaconequity.com/i/VVUS

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity

VIVUS Inc. (VVUS) is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for underserved markets in the United States. The Company's product pipeline includes three late-stage clinical products, each addressing specific components of the obesity, diabetes and sexual health markets. Its lead product in clinical development, Qnexa, has completed phase III clinical trials for the treatment of obesity and an NDA was submitted to the FDA in December 2009.

Message Board Search for VVUS: http://www.boardcentral.com/boards/VVUS

In the report, the analyst notes:

"Early in January, VVUS announced additional results of phase III avanafil study in ED showing efficacy in 15 minutes ... 'This new data further strengthens the profile and differentiation of avanafil from other currently available oral ED therapies,' VVUS CEO Leland Wilson stated in a press release. 'We knew from the pharmacokinetic profile that avanafil works very quickly; this data is exciting evidence of how fast avanafil really works.'

"VVUS reported positive results from a phase II study evaluating the safety and efficacy of Qnexa, its investigational drug for the treatment of obstructive sleep apnea (OSA)... study demonstrated statistically significant improvement in the apnea/hypopnea index (AHI - a measure of the severity of sleep apnea) in patients with OSA treated with Qnexa for 28 weeks. Additionally, Qnexa-treated patients experienced significant weight loss, improvements in blood pressure, and overnight blood oxygen levels."

To read the entire report visit: http://www.beaconequity.com/i/VVUS

See what investors are saying about VVUS at penny stock forum.

BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com

Beacon Equity Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.



            

Contact Data